861 related articles for article (PubMed ID: 17679832)
1. Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome.
Ferdinand KC
J Cardiometab Syndr; 2006; 1(2):133-40. PubMed ID: 17679832
[TBL] [Abstract][Full Text] [Related]
2. High cardiovascular risk in patients with diabetes and the cardiometabolic syndrome: mandate for statin therapy.
Gonzalez GL; Manrique CM; Sowers JR
J Cardiometab Syndr; 2006; 1(3):178-83. PubMed ID: 17679817
[TBL] [Abstract][Full Text] [Related]
3. Treating the cardiometabolic syndrome: an opportunity to provide comprehensive cardiovascular risk reduction.
Basile J; Houston M; Ferrario CM
J Cardiometab Syndr; 2006; 1(5):358-61. PubMed ID: 17679795
[No Abstract] [Full Text] [Related]
4. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
5. Recommendations for special populations: diabetes mellitus and the metabolic syndrome.
Sowers JR
Am J Hypertens; 2003 Nov; 16(11 Pt 2):41S-45S. PubMed ID: 14625160
[TBL] [Abstract][Full Text] [Related]
6. Pitavastatin in cardiometabolic disease: therapeutic profile.
Masana L
Cardiovasc Diabetol; 2013; 12 Suppl 1(Suppl 1):S2. PubMed ID: 23819752
[TBL] [Abstract][Full Text] [Related]
7. Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.
Ascaso J; Gonzalez Santos P; Hernandez Mijares A; Mangas Rojas A; Masana L; Millan J; Pallardo LF; Pedro-Botet J; Perez Jimenez F; Pintó X; Plaza I; Rubiés J; Zúñiga M
Am J Cardiovasc Drugs; 2007; 7(1):39-58. PubMed ID: 17355165
[TBL] [Abstract][Full Text] [Related]
8. Statins in cardiometabolic disease: what makes pitavastatin different?
Ginsberg H
Cardiovasc Diabetol; 2013; 12 Suppl 1(Suppl 1):S1. PubMed ID: 23819727
[TBL] [Abstract][Full Text] [Related]
9. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
[TBL] [Abstract][Full Text] [Related]
10. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
[TBL] [Abstract][Full Text] [Related]
11. Prehypertension and the cardiometabolic syndrome: is there any value in pharmacologic intervention?
Ferdinand KC
J Cardiometab Syndr; 2006; 1(2):146-8. PubMed ID: 17679828
[TBL] [Abstract][Full Text] [Related]
12. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
Querton L; Buysschaert M; Hermans MP
J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
[TBL] [Abstract][Full Text] [Related]
13. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ; ; ;
Circulation; 2004 Jul; 110(2):227-39. PubMed ID: 15249516
[TBL] [Abstract][Full Text] [Related]
14. The COSEHC™ Global Vascular Risk Management quality improvement program: first follow-up report.
Ferrario CM; Joyner J; Colby C; Exuzides A; Moore M; Simmons D; Bestermann W; Frech-Tamas F
Vasc Health Risk Manag; 2013; 9():391-400. PubMed ID: 23901282
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular risk management in type 2 diabetes of more than 10-year duration: Results of Polish ARETAEUS2-Grupa Study.
Leśniak W; Bała MM; Płaczkiewicz-Jankowska E; Topór-Mądry R; Jankowski M; Sieradzki J; Banasiak W;
Cardiol J; 2015; 22(2):150-9. PubMed ID: 25299503
[TBL] [Abstract][Full Text] [Related]
16. Pharmacotherapy of mixed dyslipidemia in the metabolic syndrome.
Nakajima K
Curr Clin Pharmacol; 2010 May; 5(2):133-9. PubMed ID: 20156152
[TBL] [Abstract][Full Text] [Related]
17. Metabolic syndrome is strongly associated with chronic subclinical inflammation in patients achieving optimal low-density lipoprotein-cholesterol levels in secondary prevention of cardiovascular disease.
Matsuo Y; Hashizume T; Shioji S; Akasaka T
Circ J; 2008 Dec; 72(12):2046-50. PubMed ID: 18946171
[TBL] [Abstract][Full Text] [Related]
18. Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study).
Erdine S; Ro YM; Tse HF; Howes LG; Aguilar-Salinas CA; Chaves H; Guindy R; Chopra P; Moller RA; Schou IM;
J Hum Hypertens; 2009 Mar; 23(3):196-210. PubMed ID: 18800143
[TBL] [Abstract][Full Text] [Related]
19. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
[TBL] [Abstract][Full Text] [Related]
20. Optimal medical management of peripheral arterial disease.
Rice TW; Lumsden AB
Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
